Topic: antibody-drug conjugates
Phase 2 data presented at ASH 2017 suggests that Roche's high expectations for its antibody-drug conjugate for non-Hodgkin lymphoma could be justified.
Daiichi Sankyo has teamed up with Glycotope to develop an antibody-drug conjugate with potential in ovarian, lung and breast cancers.
The antibody-drug conjugate specialist will use the money to take its two lead hematological cancer assets through registrational trials.
AbbVie joins forces with Bristol-Myers Squibb once again to test an experimental cancer drug with BMS' checkpoint inhibitor Opdivo.
Iontas will use its phage display libraries and other antibody discovery capabilities to provide Glythera with a key component of its planned ADCs.
The deal gives Jazz an option to pick up worldwide rights to two hematology antibody-drug conjugates and a third as-yet-unidentified program.
Celgene has decided it is best served by picking up the choicest fruits of the collaboration while leaving Sutro to go forward independently.
Ten years after taking over Agensys in a $537 million deal, Japan's Astellas has decided to pull the plug on the Santa Monica-based operation.
The drug failed to improve progression-free survival in mesothelioma, causing the stocks of Bayer’s collaborators ImmunoGen and MorphoSys to slip.
Telix has committed about $65 million in return for the exclusive right to use the antibodies to guide radioactive payloads to tumors.